506
Participants
Start Date
September 16, 2020
Primary Completion Date
August 15, 2025
Study Completion Date
December 31, 2025
Fremanezumab
"Participants weighing ≥ threshold will receive Dose A subcutaneously monthly.~Participants weighing \< threshold will receive Dose B subcutaneously monthly.~Subcutaneously monthly, confirmed or adjusted, as appropriate, based on the participant's weight every 3 months."
Teva Investigational Site 32729, Berlin
Teva Investigational Site 14276, Amherst
Teva Investigational Site 30239, Milan
Teva Investigational Site 30228, Milan
Teva Investigational Site 30226, Milan
Teva Investigational Site 14365, Baltimore
Teva Investigational Site 14323, Norfolk
Teva Investigational Site 30227, Pavia
Teva Investigational Site 14248, Raleigh
Teva Investigational Site 14377, Durham
Teva Investigational Site 14243, Atlanta
Teva Investigational Site 14258, Savannah
Teva Investigational Site 14244, Jacksonville
Teva Investigational Site 14325, Miami
Teva Investigational Site 14250, West Palm Beach
Teva Investigational Site 14255, West Palm Beach
Teva Investigational Site 40052, Tampere
Teva Investigational Site 30238, Padua
Teva Investigational Site 14374, Bristol
Teva Investigational Site 14376, Ridgeland
Teva Investigational Site 14327, Louisville
Teva Investigational Site 31270, Valencia
Teva Investigational Site 31265, Valladolid
Teva Investigational Site 14251, Ann Arbor
Teva Investigational Site 30230, Florence
Teva Investigational Site 14270, Minneapolis
Teva Investigational Site 80168, Holon
Teva Investigational Site 14263, Hoffman Estates
Teva Investigational Site 32728, Bad Homburg
Teva Investigational Site 14245, Wichita
Teva Investigational Site 40049, Kuopio
Teva Investigational Site 14360, Covington
Teva Investigational Site 14257, Oklahoma City
Teva Investigational Site 14363, Tulsa
Teva Investigational Site 14252, Austin
Teva Investigational Site 14273, Austin
Teva Investigational Site 14319, Aurora
Teva Investigational Site 14368, Colorado Springs
Teva Investigational Site 14375, Salt Lake City
Teva Investigational Site 40054, Oulu
Teva Investigational Site 80164, Safed
Teva Investigational Site 80166, Haifa
Teva Investigational Site 80167, Ramat Gan
Teva Investigational Site 80165, Tel Aviv
Teva Investigational Site 80170, Be’er Ya‘aqov
Teva Investigational Site 80169, Jerusalem
Teva Investigational Site 14246, Waltham
Teva Investigational Site 14256, Bridgeton
Teva Investigational Site 14371, New Brunswick
Teva Investigational Site 14264, Cincinnati
Teva Investigational Site 14364, Philadelphia
Teva Investigational Site 14367, Dallas
Teva Investigational Site 11182, Ottawa
Teva Investigational Site 11179, Ottawa
Teva Investigational Site 11181, Montreal
Teva Investigational Site 40053, Helsinki
Teva Investigational Site 32726, Leipzig
Teva Investigational Site 30225, Rome
Teva Investigational Site 38138, Doetinchem
Teva Investigational Site 38135, Nijmegen
Teva Investigational Site 38136, Rotterdam
Teva Investigational Site 53441, Gdansk
Teva Investigational Site 53437, Kielce
Teva Investigational Site 53443, Krakow
Teva Investigational Site 53452, Krakow
Teva Investigational Site 53440, Lublin
Teva Investigational Site 53439, Poznan
Teva Investigational Site 53451, Poznan
Teva Investigational Site 53442, Szczecin
Teva Investigational Site 31271, Barcelona
Teva Branded Pharmaceutical Products R&D LLC
INDUSTRY